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 1 
ABSTRACT 2 
 Immunophenotypic remission (IR) is a strong prognostic factor in myeloma patients. The 3 
combination of IR and conventional complete remission (CR) was retrospectively evaluated in 66 4 
patients after allografting. IR was defined as absence of monoclonal plasma cells in bone marrow 5 
aspirates by multiparameter flow-cytometry. Conditioning was non-myeloablative in 55 patients; 6 
reduced-intensity in 10 and myeloablative in 1 patient. The allograft was given upfront in 35/66 7 
(53%) patients. After a median follow-up of 7.1 years, 24 patients achieved both CR and IR (CR/IR 8 
group), 21 achieved IR but not CR with persistence of urine/serum M-component (noCR/IR group), 9 
and 21 did not achieve either CR or IR (noCR/noIR group). Median overall survival (OS) and event 10 
free survival (EFS) were “not reached” and 59 months in the CR/IR group; 64 and 16 months in the 11 
noCR/IR; and 36 and 6 months in the noCR/noIR respectively (p<0.001). Cumulative incidence of 12 
extra-medullary disease was 4,4 % in the CR/IR, 38,1% in the noCR/IR and 14,3% in the 13 
noCR/noIR groups respectively at 4 years (p<0.001). IR was a valid tool to monitor residual disease 14 
after allografting and allowed to define a cohort of patients at higher incidence of extra-medullary 15 
relapse.  16 
 17 
18 
19 
20 
  
INTRODUCTION 21 
 The increment in response rates of recent years, longer life expectancy and several treatment 22 
options in patients with multiple myeloma (MM) have drawn particular attention to the importance of an 23 
in-depth evaluation of ”complete remission” and the interest in the assessment of minimal residual disease 24 
(MRD) has been growing [1-3]. Two sensitive techniques are currently employed to evaluate MRD: 25 
qualitative and quantitative polymerase chain reaction (PCR)-based methods and multi-parameter flow-26 
cytometry. PCR-based methods have been of great value in predicting clinical outcomes in MM patients 27 
following allografting [4-7], though expensive and labor-intensive, they are characterized by higher 28 
sensitivity. A patient-specific molecular marker is, however, detected in only 60% to 70% of patients. The 29 
evaluation of MRD through immunophenotyping is more broadly applicable in the MM patients 30 
population than PCR as it involves the identification of phenotypic aberrancies in myelomatous plasma 31 
cells, which are seen in more than 90% of MM patients. However, the antibody panels used for 32 
immunophenotype analysis consist of markers recommended by experts' opinions, and only recently 33 
attempts to validate and standardize them have been made [8]. 34 
MRD studies using flow-cytometry have so far been carried out on patients treated with autologous 35 
transplantation, conventional chemotherapy or new drugs [9-13]. MRD studies in the setting of 36 
allografting are however lacking. Here, we report an analysis on the achievement of immunophenotypic 37 
response (IR) after an allograft and its prognostic impact when combined with conventional complete 38 
remission (CR). 39 
 40 
 41 
MATERIAL AND METHODS 42 
 Patients Between January 2000 and December 2011, 80 consecutive MM patients underwent an 43 
allograft at our Center. Sixty-nine out of 80 (median age 54 years, range 35-66), with a follow-up of at 44 
least 3 months were included in this study. Three were excluded from this analysis because of early 45 
  
treatment related death at 4 months post-transplant (no. 2), and because of incomplete data (no. 1). 46 
Overall, 66 patients were included and their characteristics are summarized in Table 1. Median time from 47 
diagnosis to allogeneic transplant was 13.2 months (range 6.6-101 months). Thirty-five out of 66 (43%) 48 
were treated at diagnosis according to a planned tandem “auto/allo” program and were also included in 49 
previously published prospective clinical trials [14-17]. All patients provided written informed consent to 50 
the proposed treatment and to the use of medical records for research purposes. The present study was 51 
approved by the Institutional Review Board of our Center and conducted according to the Declaration of 52 
Helsinki (NCT01440556). 53 
  54 
 Graft-vs.-host disease  Acute graft-vs.-host disease (GVHD) was diagnosed according to the 55 
recent indications of the National Institute of Health [18]. Chronic GVHD was graded as previously 56 
described [19]. 57 
  58 
 Response Assessment Disease response was assessed by urine and serum immune-fixation and 59 
bone marrow aspirates at 3, 6, 12, 18, 24 months after allografting, and yearly thereafter. Whole-body 60 
conventional radiography or magnetic resonance imaging were performed yearly or as clinically indicated 61 
(overt relapse or complaints of bone pain). Disease response and disease relapse were defined according 62 
to the European Bone Marrow Transplantation Group criteria [20]. Achievement of CR was defined as 63 
the absence of monoclonal component by immunofixation on both serum and urine, disappearance of any 64 
soft tissue plasmacytoma and less than 5% plasma cells in the bone marrow. The incidence of extra-65 
medullary disease (EMD) in first relapse post allografting was monitored, and EMD was defined as 66 
previously described [21].  67 
 First pulls of bone marrow samples had to contain at least 13000 cells/uL for flow-cytometry 68 
MRD studies. Plasma cells quantification was obtained by 4 to 6-colour staining with the following 69 
monoclonal antibodies: CD38, CD138, CD56, CD19, CD45, cyKappa, cyLambda. A FACSCanto II 70 
  
Flow-cytometer equipped with FACSDiva software (BD Biosciences, San Josè, CA) was used. A total of 71 
1 x 106 events were acquired and analyzed for each sample, as previously reported [22]. Flow-cytometry 72 
analysis had a sensitivity of 10
-4
 cells [23]. IR was defined as less than 0.01% monoclonal plasma cells in 73 
the bone marrow sample. 74 
 Assessment of CR and IR was done at best response. According to the achievement of CR and/or 75 
IR, patients were divided into 4 groups: those who achieved CR and IR (CR/IR), those who obtained CR 76 
but not IR (CR/noIR), those not in CR but in IR (noCR/IR) and those who did not achieve either CR or IR 77 
(noCR/noIR). Time to CR and IR was evaluated excluding patients who were in CR and IR at the time of 78 
transplant, respectively.  79 
 80 
Genetic abnormalities Although single evaluation of chromosome 13 deletion (del(13)) is no 81 
more considered an optimal prognostic marker, it still has value as it is frequently associated with t(4;14), 82 
del(17) or t(14;20). Thus patients presenting del(13) with/without other cytogenetic aberrations were 83 
considered as at high risk [24]. 84 
 85 
 Statistical methods Primary endpoints were overall survival (OS) and event free survival (EFS) 86 
in the 4 patient cohorts defined by the achievement of CR and/or IR. OS was defined as time from 87 
transplant to death by any cause, and EFS as the time from transplant to progression/relapse/death as a 88 
result of any cause, whichever occurred first. Alive patients were censored as of October 1
st
, 2013. OS 89 
and EFS curves were estimated by the Kaplan-Meier method and compared using the log-rank test. OS 90 
and EFS were then analyzed by the univariate and multivariate Cox proportional hazards model, 91 
comparing by the Wald test the following risk factors: age at diagnosis (>55 vs. ≤55 years), gender (male 92 
vs. female), year of diagnosis (2008-2011 vs. 2004-2007 vs. 2000-2003), number of chemotherapy 93 
regimens (≥2 vs. 1), ISS (stage III vs. I-II), Durie and Salmon stage (IIIA-IIIB vs. IA-IB-IIA-IIB), donor 94 
gender (male vs. female), donor type (matched unrelated donor vs. sibling donor), cytogenetic profile 95 
  
(high risk vs. standard risk), EMD [21] in the clinical course before allografting, occurrence of acute and 96 
chronic GVHD (any vs. none) and disease response (CR/IR, CR/noIR, noCR/IR, noCR/noIR). Six- and 97 
twelve-month landmark analyses were performed to estimate survival by disease response. The 98 
occurrence of acute and chronic GVHD and post-transplant IR and CR were treated as time-dependent 99 
variables. Cumulative incidences of developing acute GVHD, chronic GVHD, overall relapse and 100 
extramedullary relapse were estimated by the Gray test to compare the cumulative incidence curves of the 101 
main event, in the presence of a competing event (defined as death without acute or chronic GVHD or 102 
relapse occurred before the development of acute or chronic GVHD for acute and chronic GVHD, as 103 
death without previous relapse for overall relapse, as death without previous extramedullary relapse or 104 
occurence of bone relapse for extramedullary relapse) [25]. Non-relapse mortality (NRM) was defined 105 
as death without previous relapse [25]. Patient characteristics were tested using the Fisher's exact test for 106 
categorical variables and the Mann-Whitney test for continuous ones. All reported p-values were two-107 
sided, at the conventional 5% significance level. Data were analyzed as of  January 2014 by IBM SPSS 108 
21.0.0 (Chicago-IL, USA) and R 2.15.2 package cmprsk (The R Foundation for Statistical Computing, 109 
Wien-A). 110 
 111 
RESULTS 112 
 Study population At diagnosis all patients presented with measurable disease and 12 out of 66 113 
(18%) with EMD. Thirty-five out of 66 received the allograft as part of their first line treatment, whereas 114 
the remaining (31/66, 46%) were transplanted at relapse (Table 1). In 2/31 (6%) EMD presented at 115 
relapse before the allograft. Conditionings are summarized in Table 1. Post-grafting immuno-suppression 116 
consisted of calcineurine inhibitors (cyclosporine or tacrolimus) and mycophenolate mofetil in 60 (91%), 117 
and cyclosporine and methotrexate in the remaining. Patients did not receive maintenance therapies or 118 
donor lymphocyte infusion post allograft until relapse, with the exception of 6 recent patients who started 119 
lenalidomide at six months post transplant as per protocol. Due to the rather long study period, fluorescent 120 
  
in situ hybridization (FISH) was performed in only 20 (30%) patients: del(13) aberration was detectable 121 
in 6 patients, 1 patient presented del(13) associated with del(17) and t(4;14) and 1 patient resulted positive 122 
for t(4;14); the remaining 12 patients were negative for del(13).  123 
  All patients had suitable bone marrow aspirates for IR evaluation. 124 
 125 
 Non-relapse mortality and GVHD NRM of the overall population of 80 patients was 13.8% at 1 126 
and 3 years, 15.3% at 5 years. In the 66 patients who survived at least 3 months and formed the study 127 
population, NRM was 6.1%, 9.1% and 10.8% at 1, 3 and 5 years respectively. After a median follow-up 128 
of 7.1 years (range 2.6-13.2), the incidence of acute and chronic GVHD was 44.6% and 52.4%. Patients 129 
transplanted at relapse developed more acute GVHD (p=0.03), whereas those transplanted upfront 130 
developed more chronic GVHD (p=0.034). Overall, main cause of death was disease relapse in both 131 
patients transplanted upfront and at relapse. 132 
 133 
 Disease response and relapse At the time of the allograft, 9 (14%) patients were in CR and 21 134 
(32%) in IR, 5 of these were both in CR and IR. After the allograft, all 21 IR patients remained in IR and 135 
25 additional patients entered IR for a total of 45/66 (68%), whereas 24/66 (36%) patients achieved CR, 136 
of whom only 7 were in CR pre-transplant. Median time to IR was 7 months (range 1-48, no. 23), 137 
whereas median time to CR was 8 months (range 1-60, no. 17). Among the 45 patients who achieved IR, 138 
26 performed Magnetic Resonance Imaging (MRI) and 2 Computerized Tomography (CT) scans of the 139 
spine at the time of best response, 14 were in the CR/IR group and 14 in the noCR/IR group. Only 4 out 140 
of 28 MRI/TC scans showed myeloma infiltration, and all in the noCR/IR group. Seventeen patients in IR 141 
did not perform any MRI/CT scan. Twenty-one patients showed discrepant results with persistent serum 142 
and/or urine monoclonal component despite the absence of monoclonal marrow plasma cells. Overall, 143 
patients were divided into the following cohorts: 24 in CR and IR (CR/IR group); 21 in IR but not CR 144 
(noCR/IR group); 21 in neither CR nor IR (noCR/noIR group). No patient was in CR but not in IR 145 
  
(CR/noIF group) (Table 2). Among patients in the CR/IR group, 5/24 only achieved CR before IR. Given 146 
the small cohort an analysis could not be carried out. Patients in the 3 cohorts were equally balanced for 147 
age, year of transplant, disease stage, median β2microglobulin, number of previous therapies, 148 
conditioning, donor gender and type. Conditioning regimen and acute GVHD were not correlated with 149 
disease response group (p=0.703 and p=0.282, respectively), whereas chronic GVHD (p=0.047) and 150 
previous therapy lines (p=0.015) were. 151 
 Overall, at follow up, cumulative incidence of disease relapse was 32%, 50% and 62% at 152 
1, 3 and 5 years, respectively. At the same time-points, it was higher in the noCR/noIR group (67%, 81%, 153 
not applicable) as compared with the noCR/IR group (33%, 62%, 72%) and with the CR/IR group (0%, 154 
13%, 30%, p<0.001). Among patients who achieved IR, median time to clinical relapse post-transplant 155 
was 9.7 months in the noCR/IR group and 30 months in the CR/IR one. The overall incidence of extra-156 
medullary first relapse was 9%, 15% and 20% at 1, 3 and 5 years, respectively. At the same time-points, it 157 
was 5%, 14%, not applicable in the noCR/noIR; 24%, 33%, 44% in the noCR/IR; and 0%, 0%, 4% in the 158 
CR/IR group (p<0.001) (Figure 1). Sites of EMD are reported in Table 3. Fourteen (12 at diagnosis and 2 159 
at pre-transplant relapse) out of 66 (21%) developed EMD before the allograft. However, only 3 of these 160 
14 were among those who experienced EMD after the allograft. 161 
 162 
 Clinical outcomes Overall, after a median follow-up of 7.1 years (range 2.6-13.2), median OS 163 
and EFS were 5.5 and 1.4 years respectively. In patients in CR, median OS and EFS were not reached and 164 
59 months as compared with 40 and 9 months in those not in CR (p<0.001). Median OS and EFS in 165 
patients who achieved IR were 96 and 41 months as compared with 36 and 6 months in those who did not 166 
(p<0.001). Landmark analysis showed that being in IR at six months post-transplant was not statistically 167 
associated with better OS and EFS (7.5 vs. 5.0 years. p=0.132 and 4.1 vs. 1.2 years p=0.065, 168 
respectively), whereas IR at 12 months post-transplant conferred an advantage in OS (10.3 vs. 2.4 169 
p=0.018) but not in EFS (3.6 vs. 1 year, p=0.634).   170 
  
By patient cohort, median OS and EFS were not reached and 59 months in the CR/IR cohort, 64 171 
and 16 months in the noCR/IR cohort, and 36 and 6 months in the noCR/noIR cohort respectively 172 
(p<0.001, both for OS and EFS) (Figure 1). Among patients not in CR, there was a significant advantage 173 
in EFS and a trend for better OS for those who reached IR compared to the noCR/noIR group (p=0.001 174 
and p=0.063, respectively).  175 
 With the limitations of the small sample size (only 20 patients evaluated), OS in high risk patients 176 
by FISH analysis was 39 months as compared with “not reached” in standard risk patients (p=0.009), 177 
whereas EFS was not statistically significant (19 months vs. 64 months, p=0.097).  178 
 All patients with EMD at first relapse (no.13) after the allograft eventually died of disease 179 
progression. OS in patients first relapsed with EMD was significantly shorter than in those relapsed 180 
without EMD (39 vs. 57 months, p=0.034). By contrast, there was no difference in OS and EFS between 181 
newly diagnosed patients with EMD and those without. 182 
 By univariate and multivariate analysis, belonging to the CR/IR cohort was the only significant 183 
predictor for prolonged OS and EFS (p<0.001) (Table 4, Table 5).   184 
 185 
DISCUSSION 186 
 MRD analysis is currently used for evaluating treatment efficiency and patient risk stratification in 187 
several hematological malignancies [26]. In MM, not only is MRD of primary importance to assess tumor 188 
shrinkage, but it is now regarded as one of the strongest prognostic predictors, irrispective of any given 189 
treatment. MRD analysis by multicolor flow-cytometry has been introduced in many clinical trials on 190 
myeloma. The prognostic impact of achieving IR has been described after conventional chemotherapy, 191 
autografting and, more recently, after new drugs [9-13].  192 
 Despite some limitations due to its retrospective nature, our study underlines the clinical 193 
importance of achieving IR also after allografting (Figure 1). Post-transplant IR was associated with 194 
  
significantly better OS and EFS. Landmark analyses suggested that IR at 12 months post allografting had 195 
greater impact on OS than IR at 6 months. This might be explained by an ongoing and/or late occurrence 196 
of graft-vs-myeloma effect. However, in patients in IR, clinical outcomes were different in the light of CR 197 
status. OS and EFS were not reached and 59 months in the CR/IR group, and 64 and 16 months in the 198 
noCR/IR group, respectively (p<0.007 and p<0.014, Figure 1). To stress the role of IR, we also observed 199 
that patients in noCR/IR showed an intermediate clinical outcome compared with those in CR/IR and in 200 
noCR/noIR (Figure 1). IR and CR status was the only variable significantly associated with improved OS 201 
and EFS by multivariate analysis (p=0.001), whereas GVHD, the number of previous therapy lines, 202 
conditioning regimen, and year of transplant were not (Table 4, Table 5).Other authors reported similar 203 
outcomes between patients who were MRD negative but not in CR and those MRD positive [13]. Paiva et 204 
al. [11] reported 21% of patients in IR with persistent positive immunofixation after autografting. 205 
Moreover, progression free survival (PFS) was progressively shorter, 71, 65, and 37 months, in patients in 206 
IR/CR, in IR/noCR and in noIR/CR respectively (p=0.001). This study clearly showed that the 207 
achievement of remission by flow-cytometry had a higher prognostic value than remission by 208 
immunofixation. In our study, we cannot draw such a definitive conclusion on the role of IR, given the 209 
lack of patients in CR but not in IR. 210 
 The discrepancy between IR and not CR was observed in 32% of our transplant patients. This 211 
finding may be explained by a number of reasons. It may partly be argued that bone marrow aspirates do 212 
not systemically represent the marrow status and areas of marrow disease may persist. It may however be 213 
more plausible that residual extra-medullary plasma cells continue secreting monoclonal 214 
immunoglobulins in sanctuary sites where agents with anti-myeloma activity and/or a potential graft-vs.-215 
myeloma may have little or slower effect. This hypothesis is supported by a higher incidence of extra-216 
medullary relapse in the IR/noCR cohort: 44% in noCR/IR group vs. 4% in CR/IR group at 5 years 217 
(p<0.001). A high incidence of EMD following allografting after reduced-intensity conditioning was 218 
previously reported. In a series of 70 patients enrolled in a Spanish study, extra-medullary involvement 219 
was documented in 10 out of the 27 patients at first relapse (37%) [27]. Interestingly, the incidence of 220 
  
extra-medullary relapses was higher in patients who had developed chronic GVHD. Importantly, these 221 
patients had no evidence of disease recurrence in the marrow at the time of relapse. The Authors 222 
suggested that graft-vs.-myeloma effects may have been more efficient in the marrow or, alternatively, 223 
that monoclonal plasma cells involved in extra-medullary relapse were more resistant to donor T-cells. In 224 
another multi-center study, Minnema et al. reported an incidence of EMD of 20.4% in 54 relapsed MM 225 
patients from a total group of 172 treated with sequential autologous-allogeneic non-myeloablative 226 
transplantation [28]. Interestingly, no association with chronic GVHD and EMD at relapse was found. In 227 
our experience, chronic GVHD did not impact on extra-medullary relapse. Overall, the association 228 
between chronic GVHD and graft-vs.-myeloma effects, is still debated [29].   229 
 Finally, the recent observation of a possible increase of the occurrence of EMD, especially after 230 
multiple relapses, may partly be explained by the current natural history of myeloma where patients 231 
commonly live longer as compared to past decades [30]. A study on 1003 MM patients showed an 232 
increase in EMD incidence in the period 2000-2007 as compared with previous years raising concerns, 233 
despite a dramatic improvement in OS, about a correlation with the use of novel agents with potent anti-234 
myeloma activity and/or a greater use of high-dose therapy [30]. However, the observation that the 235 
increase was evident both at diagnosis and at relapse suggests that other factors are contributory [31]. To 236 
reduce the risk of bias when comparing the patient cohorts of our study, we particularly focused on the 237 
presence of EMD at diagnosis and at first relapse post-transplant. In our series, the presence of EMD at 238 
diagnosis did not correlate with a higher risk of EMD development post transplant and only the noCR/IR 239 
status was significantly associated with extra-medullary relapse. Though EMD before allografting did not 240 
impact on survival, post transplant extra-medullary relapse was associated with poorer outcome in 241 
comparison with bone relapse (OS 39 vs. 57 months, p=0.034).  242 
 Although the potential role of positron emission tomography integrated with computed 243 
tomography (PET/CT) in the assessment of MM continues to be a matter of debate [32], it may be 244 
particularly informative to early diagnose EMD, together with other readily available laboratory assays 245 
  
such as serum free light chains assay [33]. Patients in IR/noCR could be ideal candidates for a clinical 246 
follow up that routinely includes PET/CT to possibly detect extra-medullary relapse before the occurrence 247 
of symptoms.  248 
 In conclusion, evaluation of MRD by flow-cytometry is a sensitive prognostic tool after 249 
allografting and should routinely be introduced in clinical practice. The achievement of IR is associated 250 
with better clinical outcomes. Moreover, the combination of IR and CR is helpful to identify a subset of 251 
patients (IR-noCR) at higher risk of developing extra-medullary relapse who may benefit from a more 252 
stringent follow up and consolidation treatment with new agents [34,35].  253 
 254 
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FIGURE LEGEND 368 
  
Figure 1. Clinical outcomes in three cohorts of patients defined by achievement of complete 369 
clinical remission (CR) and immunophenotipic remission (IR): patients in CR and IR (CR/IR) 370 
(green line); patients not in CR but in IR (blue line); patients not in CR and not in IR (pink line) 371 
